Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (the "**Company**" and its subsidiaries, the "**Group**") pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Reference is made to the announcement (the "**Previous Announcement**") and circular (the "**Circular**") of the Company, both dated 5 June 2026, in relation to, among other things, the proposed election of Mr. Chen Liang ("**Mr. Chen**") as an Independent Non-executive Director of the Company.

Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Previous Announcement and the Circular.

ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of the Company is pleased to announce that resolution number 9 regarding the election of Mr. Chen as an Independent Non-executive Director was approved at the AGM held on 26 June 2026. The election of Mr. Chen as an Independent Non-executive Director has become effective on the date of the AGM, being 26 June 2026. Poll results of the AGM are set out in the poll results announcement of the Company dated 26 June 2026.

The biographical details and other relevant information regarding Mr. Chen are set out in the Previous Announcement and the Circular. As at the date of this announcement, there has been no change to such information save as otherwise disclosed in this announcement.

The Company will enter into a service contract with Mr. Chen in relation to his election as an Independent Non-executive Director for a term commencing from the date of approval of his election at the AGM, being 26 June 2026, and expiring on the conclusion of the fourth session of the Board. This term of office is determinable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the Articles of Association and the Listing Rules. Under the terms of the service contract, the director's fee payable to Mr. Chen will be RMB200,000 per annum, which was determined with reference to his duties and responsibilities in the Company and prevailing market

conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Mr. Chen has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Listing Rules requiring the prior approval of Shareholders at general meetings, with the Company.

Mr. Chen has confirmed that: (i) he has satisfied all the standards for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters concerning Mr. Chen's election as an Independent Non-executive Director that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to extend a warm welcome to Mr. Chen for joining the Board.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board is pleased to announce that, following the resolution regarding the election of Mr. Chen as an Independent Non-executive Director being passed at the AGM, with effect from 26 June 2026, Mr. Li Zhongxian is elected as the chairman of the Audit Committee and the Remuneration and Appraisal Committee and a member of the Strategic and ESG Committee, and Mr. Chen is elected as a member of the Audit Committee and the Compliance Committee. Both terms shall commence from the approval date of the general meeting, being 26 June 2026, until the end of term of the fourth session of the Board.

Following the above changes, the composition of the Audit Committee, the Remuneration and Appraisal Committee, the Strategic and ESG Committee and the Compliance Committee will be as follows:

(i) The Audit Committee comprises two Independent Non-executive Directors, namely Mr. Li Zhongxian (chairman of the Audit Committee) and Mr. Chen Liang, and one non-executive Director, namely Mr. Tang Yi;

(ii) The Remuneration and Appraisal Committee comprises three Independent Non-executive Directors, namely Mr. Li Zhongxian (chairman of the Remuneration and Appraisal Committee), Dr. Yang Jin and Dr. Feng Xiaoyuan, and two executive Directors, namely Mr. Xiong Jun and Dr. Zou Jianjun;

(iii) The Strategic and ESG Committee comprises three executive Directors, namely Mr. Xiong Jun (chairman of the Strategic and ESG Committee), Dr. Zou Jianjun and Dr. Wang Gang, and two Independent Non-executive Directors, namely Dr. Feng Xiaoyuan and Mr. Li Zhongxian;

(iv) The Compliance Committee comprises three Independent Non-executive Directors, namely Ms. Lu Kun (chairman of the Compliance Committee), Mr. Li Zhongxian and Mr. Chen Liang.

The Board would like to take this opportunity to extend a warm welcome to Mr. Li Zhongxian and Mr. Chen for taking up new positions.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 26 June 2026

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive directors.

* *For identification purpose only*